Company profile: Triveni Bio
1.1 - Company Overview
Company description
- Provider of genetically informed functional antibody therapeutics for immunological and inflammatory disorders, supported by a proprietary data platform that leverages public and private datasets to identify therapeutic targets, predict patient subpopulations, and provide disease insights; lead program TRIV-509 targets kallikreins 5 and 7 for atopic dermatitis and other barrier disorders.
Products and services
- Lead Antibody Program (TRIV-509): A dual-target functional antibody that targets kallikreins 5 and 7 to treat atopic dermatitis and barrier disorders by impacting skin function and reducing inflammation
- Genetically Informed Therapeutics: Genetics-informed functional antibody therapeutics engineered to treat immunological and inflammatory disorders, employing a precision medicine approach grounded in human genetics
- Proprietary Data Platform: A proprietary data platform that leverages public and private datasets to identify therapeutic targets, predict patient subpopulations, and deliver disease insights to guide antibody programs
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Triveni Bio
DBV Technologies
HQ: France
Website
- Description: Provider of investigational epicutaneous immunotherapy products for food allergies and other immunological disorders via the Viaskin technology platform, including Viaskin Peanut, a patch delivering small amounts of peanut protein to the skin. Also developing Viaskin-based approaches for other food allergies, an investigational diagnostic for non-IgE-mediated milk allergy, and non-invasive vaccine delivery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DBV Technologies company profile →
Talaris Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology engaged in developing innovative cellular therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Talaris Therapeutics company profile →
Immunic Therapeutics
HQ: United States
Website
- Description: Provider of selective oral immunology therapies, developing: Vidofludimus Calcium (IMU-838), an investigational oral drug for multiple sclerosis and other chronic inflammatory and autoimmune diseases with neuroprotective, anti-inflammatory and anti-viral effects; IMU-856, a Sirtuin 6–targeting small molecule to restore intestinal barrier and regenerate bowel epithelium for gastrointestinal diseases; and IMU-381, a next-generation GI candidate in preclinical testing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunic Therapeutics company profile →
Corbus Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage therapeutics targeting inflammatory and fibrotic diseases, with programs in oncology and obesity. Pipeline includes CRB-701, a next-generation Nectin-4-targeting ADC in trials for advanced solid tumors; CRB-601, an anti-integrin monoclonal antibody blocking TGFβ activation on cancer cells; and CRB-913, a peripherally restricted CB1 inverse agonist for obesity with IND planned.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Corbus Pharmaceuticals company profile →
Deka Biosciences
HQ: United States
Website
- Description: Provider of cytokine therapy platforms, including Diakine™ combining cytokines in a single treatment for cancer and inflammatory diseases; an oncology platform with disease-targeting scaffolds that link cytokines to stimulate the immune system; an anti-inflammatory platform targeting specific tissue markers; precision medicine using genetic tests to personalize Diakines™; and manufacturing via a unique scaffold for higher yields and lower costs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Deka Biosciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Triveni Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Triveni Bio
2.2 - Growth funds investing in similar companies to Triveni Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Triveni Bio
4.2 - Public trading comparable groups for Triveni Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →